Kazia Therapeutics Ltd ADR - KZIA

SEC Filings Our KZIA Tweets

About Gravity Analytica

Recent News

  • 09.22.2026 - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
  • 09.22.2026 - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
  • 09.09.2026 - Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
  • 09.09.2026 - Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Recent Filings

  • 09.22.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.22.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.22.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.22.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 09.22.2026 - EX-99.1 EX-99.1
  • 09.18.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.18.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.18.2026 - 424B3 Prospectus [Rule 424(b)(3)]
  • 09.18.2026 - 424B3 Prospectus [Rule 424(b)(3)]